Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | DUT | P33316 | 2/20 | 0.51 |
| ▸ | NPY2R | P49146 | 6/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | ABHD11 | Q8NFV4 | 1/20 | 0.42 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15456860 | 1.00 | LMNA (0.66) | LMNADUTNPY2RL3MBTL1ATM | |
| SCHEMBL26398494 | 0.90 | LMNA (0.55) | LMNADUTNPY2RL3MBTL1HCRTR2 | |
| SCHEMBL26398497 | 0.90 | LMNA (0.55) | LMNADUTNPY2RL3MBTL1HCRTR2 | |
| SCHEMBL15456867 | 0.86 | LMNA (0.49) | LMNANPY2RTSHRMEN1KMT2A | |
| SCHEMBL20208338 | 0.84 | LMNA (0.70) | LMNADUTL3MBTL1ATMHCRTR2 | |
| SCHEMBL3934708 | 0.82 | LMNA (0.44) | LMNADUTMEN1KMT2AKDM4E | |
| SCHEMBL21330372 | 0.82 | LMNA (0.74) | LMNADUTL3MBTL1ATMMEN1 | |
| SCHEMBL21330374 | 0.82 | LMNA (0.74) | LMNADUTL3MBTL1ATMMEN1 | |
| SCHEMBL5266516 | 0.79 | LMNA (0.70) | LMNADUTL3MBTL1ATMMEN1 | |
| SCHEMBL23052661 | 0.79 | DUT (0.54) | LMNADUTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670225-B2 | HIV-1 protease inhibitors and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670225-B2 | HIV-1 protease inhibitors and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170088555-A1 | HIV-1 PROTEASE INHIBITORS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2017-03-30 | — | — | US | disclosed |
| US-20170088555-A1 | HIV-1 PROTEASE INHIBITORS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088555-A1 | HIV-1 PROTEASE INHIBITORS AND USES THEREOF | PRSS1, XPNPEP1, CTRL | LMNA 2415/4885DUT 3036/4885NPY2R 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.